glp 1 and heart disease Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update GLP-1: Beyond the Weight Loss

This metabolic improvement helps stabilize blood sugar levels throughout the day, reducing energy crashes that often trigger unhealthy snacking

There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape

Sphingosine, considered the backbone of sphingolipids, is a key component of cell membranes, and involved in cell signaling, membrane structure, and are associated with cell-growth arrest and the induction of cell death 92,93

Pairs Well NAD+ NAD+ supports cellular energy and mitochondrial health - a complementary baseline for cardiovascular and metabolic research adjacent to sexual-function studies